BioCryst Pharmaceuticals, Inc. (BCRX)
NASDAQ: BCRX · Real-Time Price · USD
9.70
-0.12 (-1.22%)
At close: Aug 31, 2026, 4:00 PM EDT
9.55
-0.15 (-1.55%)
After-hours: Aug 31, 2026, 7:57 PM EDT

BioCryst Pharmaceuticals Cash Flow Statement

Millions USD. Fiscal year is Jan - Dec.

Operating Activities

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Jun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Net Income
-384.67263.86-88.88-226.54-247.12-184.06
Depreciation & Amortization
3.83.493.012.872.250.89
Other Amortization
-0.65-----
Loss (Gain) From Sale of Assets
-4.12-4.12----
Asset Writedown & Restructuring Costs
698.36--1.55--
Loss (Gain) From Sale of Investments
-1.96-4.33-11.47-10.26-1.78-0
Loss (Gain) on Equity Investments
17.5517.55----
Stock-Based Compensation
73.1185.0765.4155.6244.734.64
Other Operating Activities
46.3742.7567.19114.0399.03-1.75
Change in Accounts Receivable
-17.47-36.81-22.7-6.1-21.47-20.82
Change in Inventory
-11.4-1.64-4.16-1.45-12.42-8.77
Change in Accounts Payable
4.6157.814.7812.53-22.3639.41
Change in Unearned Revenue
10.79---1.23-0.111.28
Change in Other Net Operating Assets
-58.19-76.26-75.2-36.16-2.58-2.99
Operating Cash Flow
376.14347.37-52.02-95.14-161.85-142.16
Operating Cash Flow Growth
2136.64%-----

Investing Activities

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Jun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Capital Expenditures
-2.76-2.47-1.12-2.17-1.35-2.39
Sale of Property, Plant & Equipment
0.550.55----
Divestitures
-6.18-6.18----
Investment in Securities
49.16-5.5953.72-129.33-126.8918.19
Investing Cash Flow
-448.71-13.6952.59-131.5-128.2415.8

Financing Activities

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Jun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Long-Term Debt Issued
---30073.07293.87
Long-Term Debt Repaid
--334.76-1.7-262.88--
Net Debt Issued (Repaid)
127.48-334.76-1.737.1273.07293.87
Issuance of Common Stock
29.119.173.488.6814.9665.79
Repurchase of Common Stock
-11.51-8.85-7.54-2.17--
Other Financing Activities
-20.45-15.5--11.15--
Financing Cash Flow
124.63-349.93-5.7632.4988.03359.67

Net Cash Flow

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Jun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Foreign Exchange Rate Adjustments
-0.651.27-0.940.360.570.07
Net Cash Flow
66.46-14.99-6.12-193.79-201.5233.39

Free Cash Flow

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Jun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Free Cash Flow
373.38344.9-53.14-97.31-163.2-144.54
Free Cash Flow Growth
2268.99%-----
Free Cash Flow Margin
39.70%39.42%-11.79%-29.36%-60.26%-91.97%
Free Cash Flow Per Share
1.631.58-0.26-0.51-0.88-0.81
Levered Free Cash Flow
323.67256.4211.95-67.23-141.51-122.67
Unlevered Free Cash Flow
370.72305.7273.520.42-79.58-85.61

Additional Metrics

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Jun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Cash Interest Paid
21.4323.7430.3822.14-0.9
Cash Income Tax Paid
4.632.81.61.433.540.12
Change in Working Capital
-71.66-56.9-87.28-32.4-58.958.12
SEC Filings: 10-K · 10-Q